May 13 (Reuters) - Catabasis Pharmaceuticals Inc :
* CATABASIS PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
* Q1 LOSS PER SHARE $7.60
* CATABASIS - ASSUMING APPROVAL OF PREFERRED STOCK CONVERSION, EXPECTS IT HAS SUFFICIENT CASH TO FUND CURRENT OPERATING PLAN THROUGH 2023
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。